During the recent session, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s traded shares were 0.45 million, with the beta value of the company hitting 1.35. At the last check today, the stock’s price was $1.76, reflecting an intraday loss of -2.39% or -$0.04. The 52-week high for the LXRX share is $3.73, that puts it down -111.93 from that peak though still a striking 47.73% gain since the share price plummeted to a 52-week low of $0.92. The company’s market capitalization is $635.10M, and the average intraday trading volume over the past 10 days was 2.97 million shares, and the average trade volume was 2.90 million shares over the past three months.
Lexicon Pharmaceuticals Inc (LXRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.67. LXRX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.16.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Lexicon Pharmaceuticals Inc (LXRX) registered a -2.39% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.39% in intraday trading to $1.76, hitting a weekly high. The stock’s 5-day price performance is -3.99%, and it has moved by -13.02% in 30 days. Based on these gigs, the overall price performance for the year is -2.93%. The short interest in Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) is 24.53 million shares and it means that shorts have 7.37 day(s) to cover.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
Statistics show that Lexicon Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. Lexicon Pharmaceuticals Inc (LXRX) shares have gone down -29.16% during the last six months, with a year-to-date growth rate less than the industry average at 12.66% against 18.00. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 23.80% this quarter and then jump 20.00% in the quarter after that. In the rating firms’ projections, revenue will increase 1,261.30% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 5.22M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 8.41M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 162k and 702k respectively. In this case, analysts expect current quarter sales to grow by 3,122.20% and then jump by 1,098.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 6.80%. While earnings are projected to return 14.47% in 2024.
LXRX Dividends
Lexicon Pharmaceuticals Inc is due to release its next quarterly earnings on 2024-Nov-06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
Lexicon Pharmaceuticals Inc insiders own 1.15% of total outstanding shares while institutional holders control 79.19%, with the float percentage being 80.11%. ARTAL GROUP S.A. is the largest shareholder of the company, while 172.0 institutions own stock in it. As of 2024-06-30, the company held over 175.1 million shares (or 71.3555% of all shares), a total value of $294.17 million in shares.
The next largest institutional holding, with 38.69 million shares, is of FMR LLC’s that is approximately 15.7656% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $64.99 million.
